Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment.
Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. Sakuraba A, et al. Among authors: matsui t. Am J Gastroenterol. 2009 Dec;104(12):2990-5. doi: 10.1038/ajg.2009.453. Epub 2009 Sep 1. Am J Gastroenterol. 2009. PMID: 19724269 Clinical Trial.
Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.
Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Watanabe K, et al. Among authors: matsui t. J Gastroenterol. 2020 Mar;55(3):291-306. doi: 10.1007/s00535-019-01647-w. Epub 2019 Dec 13. J Gastroenterol. 2020. PMID: 31836930 Free PMC article. Clinical Trial.
A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis.
Ashida T, Kohgo Y, Munakata A, Noguchi M, Iizuka B, Endo Y, Hanai H, Yoshikawa T, Matsumoto T, Aoyama N, Matsui T, Mitsuyama K, Hibi T. Ashida T, et al. Among authors: matsui t. Transfus Apher Sci. 2011 Apr;44(2):113-7. doi: 10.1016/j.transci.2011.01.001. Transfus Apher Sci. 2011. PMID: 21402309 Clinical Trial.
Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease.
Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Hibi T, et al. Among authors: matsui t. Inflamm Bowel Dis. 2012 Aug;18(8):1480-7. doi: 10.1002/ibd.21886. Epub 2011 Oct 10. Inflamm Bowel Dis. 2012. PMID: 21987418
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.
Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, Yoshinari T, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Hibi T, et al. Among authors: matsui t. J Gastroenterol. 2014 Feb;49(2):254-62. doi: 10.1007/s00535-013-0807-0. Epub 2013 Apr 20. J Gastroenterol. 2014. PMID: 23604570 Clinical Trial.
Hematologic malignancies in the Japanese patients with inflammatory bowel disease.
Fukata N, Okazaki K, Omiya M, Matsushita M, Watanabe M; Members of the Ministry of Health and Welfare of Japan’s Inflammatory Bowel Diseases Study Group. Fukata N, et al. J Gastroenterol. 2014 Sep;49(9):1299-306. doi: 10.1007/s00535-013-0873-3. Epub 2013 Aug 19. J Gastroenterol. 2014. PMID: 23955181
4,235 results